Latest Regulatory Impact News

Botanix Pharmaceuticals has clarified that recent share price movements are linked to a rumored US executive order on drug pricing, confirming no undisclosed material information. The company reassures investors of compliance with ASX disclosure rules amid market speculation.

Botanix Pharmaceuticals clarifies its lead product Sofdra is unlikely to face price cuts under the proposed US executive order on drug pricing, citing its exclusive US market approval and distinct formulations abroad.

EDU Holdings reports a 25% increase in total student enrolments for Term 2, 2025 at its Australian Learning Group, even as new enrolments decline amid tighter visa restrictions.

SomnoMed Limited reported a robust 23.2% revenue increase in Q3 FY25, reaffirming its full-year guidance while actively addressing new US tariffs through potential duty-free exemptions.

Carbonxt Group advances commissioning of its Kentucky activated carbon plant while securing $2.5 million in fresh capital and reporting strong sales growth and cost savings ahead of FY26.

Donaco International reported a modest revenue and EBITDA decline in Q3 FY2025 but strengthened its cash reserves. Meanwhile, the company agreed to a full acquisition scheme at a significant premium, setting the stage for shareholder decisions amid regulatory uncertainties.

Carbonxt Group Limited has initiated a $2 million Share Purchase Plan following successful capital raises, aiming to bolster its Kentucky activated carbon facility as it nears commercial production.

Resolute Mining delivered a solid 2024 with record cash flows and slightly higher gold production, but faces rising costs from Mali’s new Mining Code and a $160 million government settlement. The company plans lower 2025 output as Mako mining winds down, focusing on cash flow and exploration.

Xanadu Mines has lodged a comprehensive NI 43-101 technical report for its Kharmagtai Copper-Gold Project, revealing key differences in production and economic outcomes compared to earlier ASX disclosures due to regulatory standards.